Australian Broker Call
Produced and copyrighted by at www.fnarena.com
May 23, 2018
Access Broker Call Report Archives here
COMPANIES DISCUSSED IN THIS ISSUE
Click on symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
Last Updated: 12:47 PM
Your daily news report on the latest recommendation, valuation, forecast and opinion changes.
This report includes concise but limited reviews of research recently published by Stockbrokers, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end.
For more info about the different terms used by stockbrokers, as well as the different methodologies behind similar sounding ratings, download our guide HERE
Today's Upgrades and Downgrades
FBU - | FLETCHER BUILDING | Upgrade to Neutral from Underperform | Macquarie |
OFX - | OZFOREX GROUP | Downgrade to Neutral from Outperform | Macquarie |
STO - | SANTOS | Downgrade to Sell from Neutral | Citi |
BBN BABY BUNTING GROUP LIMITED
Apparel & Footwear
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.48
Morgan Stanley rates BBN as Overweight (1) -
Toys "R" Us Australia has entered voluntary administration after a sale process failed to find a buyer. Morgan Stanley considers this poses a risk to near-term earnings for Baby Bunting but is a positive in terms of the long-run industry structure.
Toys "R" Us is expected to clear $15-80m in baby-related inventory across the remainder of FY18 and the first quarter of FY19. Morgan Stanley expects Baby Bunting will refrain from price matching and the impact is likely to be felt in sales rather than gross margin.
Overweight retained. Target is $2.10. Industry view: In Line.
Target price is $2.10 Current Price is $1.48 Difference: $0.62
If BBN meets the Morgan Stanley target it will return approximately 42% (excluding dividends, fees and charges).
Current consensus price target is $1.59, suggesting upside of 7.3% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY18:
Morgan Stanley forecasts a full year FY18 dividend of 5.60 cents and EPS of 8.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 7.9, implying annual growth of -18.6%. Current consensus DPS estimate is 5.8, implying a prospective dividend yield of 3.9%. Current consensus EPS estimate suggests the PER is 18.7. |
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 dividend of 7.80 cents and EPS of 11.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.7, implying annual growth of 22.8%. Current consensus DPS estimate is 7.0, implying a prospective dividend yield of 4.7%. Current consensus EPS estimate suggests the PER is 15.3. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CLH COLLECTION HOUSE LIMITED
Business & Consumer Credit
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.57
Morgans rates CLH as Hold (3) -
The company has entered a transaction with Balbec Capital to assign part of its arrangement book for $19.5m. The company will receive the cash up front and intends to reinvest this in PDLs. Collection House has the option to repurchase the residual rights to collect the remaining arrangements at the end of the five-year agreement.
Morgans considers the deal positive, as the company now has a more flexible balance sheet. Hold rating maintained. Target rises to $1.55 from $1.40.
Target price is $1.55 Current Price is $1.57 Difference: minus $0.02 (current price is over target).
If CLH meets the Morgans target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
The company's fiscal year ends in June.
Forecast for FY18:
Morgans forecasts a full year FY18 dividend of 8.20 cents and EPS of 18.00 cents. |
Forecast for FY19:
Morgans forecasts a full year FY19 dividend of 8.50 cents and EPS of 17.00 cents. |
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FBU FLETCHER BUILDING LIMITED
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $5.99
Macquarie rates FBU as Upgrade to Neutral from Underperform (3) -
The company has completed its NZ$750m entitlement offer which Macquarie believes will provide a firm of platform on which to execute its strategic objectives. The broker believes the company's move to consolidate its product and geographic spread will be well received.
More about this strategy will be learned in June. Macquarie upgrades to Neutral from Underperform. Target is raised to NZ$6.54 from NZ$5.30.
Current Price is $5.99. Target price not assessed.
Current consensus price target is N/A
The company's fiscal year ends in June.
Forecast for FY18:
Macquarie forecasts a full year FY18 dividend of 0.00 cents and EPS of minus 9.71 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -6.2, implying annual growth of N/A. Current consensus DPS estimate is 2.9, implying a prospective dividend yield of 0.5%. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 24.97 cents and EPS of 41.61 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 50.2, implying annual growth of N/A. Current consensus DPS estimate is 25.1, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 11.9. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GOZ GROWTHPOINT PROPERTIES AUSTRALIA
Infra & Property Developers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $3.43
Ord Minnett rates GOZ as Initiation of coverage with Hold (3) -
Ord Minnett initiates coverage with a Hold rating and $3.20 target. The broker notes, since its inception in 2009, Growthpoint has increased its asset base fivefold and re-weighted its portfolio towards office.
Negative reversion from 10% over-renting in its industrial portfolio, based on the broker's observations, should reduce the growth rate. As a result, earnings and distribution growth of 2% per annum is forecast over 3-5 years.
This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.
Target price is $3.20 Current Price is $3.43 Difference: minus $0.23 (current price is over target).
If GOZ meets the Ord Minnett target it will return approximately minus 7% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $3.15, suggesting downside of -8.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Ord Minnett forecasts a full year FY18 dividend of 22.00 cents and EPS of 23.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.2, implying annual growth of -45.7%. Current consensus DPS estimate is 22.0, implying a prospective dividend yield of 6.4%. Current consensus EPS estimate suggests the PER is 14.8. |
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 22.00 cents and EPS of 24.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.6, implying annual growth of 1.7%. Current consensus DPS estimate is 22.1, implying a prospective dividend yield of 6.4%. Current consensus EPS estimate suggests the PER is 14.5. |
Market Sentiment: -0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.34
Citi rates HSO as Neutral (3) -
Healthscope has yet again issued a profit warning, which triggers further lowered estimates, but Citi analysts have also lifted their price target "to reflect corporate action premium". The rating remains Neutral.
Given the highly conditional nature of the two offers that have been made public, Citi analysts side with company management in not allowing for due diligence. They believe higher offers could be forthcoming. New target $2.45 (was $1.80).
Target price is $2.45 Current Price is $2.34 Difference: $0.11
If HSO meets the Citi target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $2.33, suggesting downside of -0.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Citi forecasts a full year FY18 dividend of 6.70 cents and EPS of 9.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.0, implying annual growth of -4.3%. Current consensus DPS estimate is 6.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY19:
Citi forecasts a full year FY19 dividend of 6.70 cents and EPS of 10.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.1, implying annual growth of 12.2%. Current consensus DPS estimate is 7.1, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 23.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Credit Suisse rates HSO as Neutral (3) -
Healthscope intends to close Geelong and Cotham private hospitals in Victoria and take an impairment on Frankston Private. The company has also lowered FY18 guidance and signalled 10% growth in hospital operating earnings in FY19.
Healthscope has denied due diligence to BGH and Brookfield based on their current bids.
The company is assessing a sale and lease back opportunity for the property portfolio. While this may free up capital, Credit Suisse suspects the potential value of the portfolio may be significantly reduced. Neutral rating and $2.36 target maintained.
Target price is $2.36 Current Price is $2.34 Difference: $0.02
If HSO meets the Credit Suisse target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $2.33, suggesting downside of -0.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Credit Suisse forecasts a full year FY18 dividend of 6.44 cents and EPS of 9.25 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.0, implying annual growth of -4.3%. Current consensus DPS estimate is 6.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY19:
Credit Suisse forecasts a full year FY19 dividend of 6.76 cents and EPS of 9.95 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.1, implying annual growth of 12.2%. Current consensus DPS estimate is 7.1, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 23.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Deutsche Bank rates HSO as Hold (3) -
Yet another profit warning triggers yet another "disappointing" response from Deutsche Bank analysts. They retain the Hold rating on ongoing corporate appeal.
Guidance provided for FY19 is also below expectations. The broker notes the company has effectively rejected both offers from current suitors. Target price has lost 5c to $2.
Target price is $2.00 Current Price is $2.34 Difference: minus $0.34 (current price is over target).
If HSO meets the Deutsche Bank target it will return approximately minus 15% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $2.33, suggesting downside of -0.2% (ex-dividends)
Forecast for FY18:
Current consensus EPS estimate is 9.0, implying annual growth of -4.3%. Current consensus DPS estimate is 6.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY19:
Current consensus EPS estimate is 10.1, implying annual growth of 12.2%. Current consensus DPS estimate is 7.1, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 23.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates HSO as Equal-weight (3) -
Healthscope has rejected requests for due diligence from BGH and Brookfield and intends to re-organise its assets. FY18 operating earnings are revised down around -5%. The company will incur a loss from Geelong, Cotham and Frankston private hospitals.
The near-term fundamentals are likely to take a backseat while the assets are re-organised and Morgan Stanley expects a premium to remain in the shares.
Equal-weight. Target is reduced to $2.23 from $2.36. Industry view is In-Line.
Target price is $2.23 Current Price is $2.34 Difference: minus $0.11 (current price is over target).
If HSO meets the Morgan Stanley target it will return approximately minus 5% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $2.33, suggesting downside of -0.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Morgan Stanley forecasts a full year FY18 dividend of 6.90 cents and EPS of 9.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.0, implying annual growth of -4.3%. Current consensus DPS estimate is 6.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 dividend of 7.50 cents and EPS of 10.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.1, implying annual growth of 12.2%. Current consensus DPS estimate is 7.1, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 23.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates HSO as Hold (3) -
The company has concluded its portfolio review, with the need for rationalisation flagged and underperforming Victorian assets in focus. Both the Geelong Private and the Cotham Private hospitals will close. Healthscope will also take an impairment on Frankston Private.
Asian pathology will probably be divested. FY18 forecasts are downgraded by -4-5%. Morgans suggests there are a lot of moving parts and it is difficult to know if the two would-be suitors will sweeten their current offers.
The broker maintains a Hold rating and reduces the target to $2.30 from $2.42.
Target price is $2.30 Current Price is $2.34 Difference: minus $0.04 (current price is over target).
If HSO meets the Morgans target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $2.33, suggesting downside of -0.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Morgans forecasts a full year FY18 dividend of 6.70 cents and EPS of 10.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.0, implying annual growth of -4.3%. Current consensus DPS estimate is 6.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY19:
Morgans forecasts a full year FY19 dividend of 7.40 cents and EPS of 11.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.1, implying annual growth of 12.2%. Current consensus DPS estimate is 7.1, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 23.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates HSO as Hold (3) -
The board has decided not to pursue either of the offers for Healthscope. Ord Minnett believes a successful takeover would have been in the best interests of shareholders, particularly in light of the further deterioration in earnings.
Nevertheless, the decision by the board is considered sound, given the conditional nature of the bids and the potential for a bidding war. The broker would be less comfortable with any move by the business to pursue a strategy that would undermine external interest, notably by undertaking the sale and lease back of properties, which is under consideration.
Hold rating maintained. Target rises to $2.50 from $2.36.
This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.
Target price is $2.50 Current Price is $2.34 Difference: $0.16
If HSO meets the Ord Minnett target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $2.33, suggesting downside of -0.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY18:
Ord Minnett forecasts a full year FY18 dividend of 7.00 cents and EPS of 5.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.0, implying annual growth of -4.3%. Current consensus DPS estimate is 6.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 7.00 cents and EPS of 9.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.1, implying annual growth of 12.2%. Current consensus DPS estimate is 7.1, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 23.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
JHX JAMES HARDIE INDUSTRIES N.V.
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $22.91
Citi rates JHX as Buy (1) -
Citi analysts seem pleased with what they believe is a "solid" Q4 performance from the company, accompanied by a strong start into the new financial year. Recently acquired Fermacell added to the positive picture.
The analysts have slightly reduced forecasts, but highlight their expectation remains for double digit earnings growth in the years ahead. The wait continues for a new CEO. Buy recommendation and $27 price target both unchanged.
Target price is $27.00 Current Price is $22.91 Difference: $4.09
If JHX meets the Citi target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $24.79, suggesting upside of 8.2% (ex-dividends)
The company's fiscal year ends in March.
Forecast for FY19:
Citi forecasts a full year FY19 dividend of 61.90 cents and EPS of 102.64 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 100.1, implying annual growth of N/A. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 22.9. |
Forecast for FY20:
Citi forecasts a full year FY20 dividend of 70.92 cents and EPS of 116.57 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.5, implying annual growth of 14.4%. Current consensus DPS estimate is 68.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 20.0. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Credit Suisse rates JHX as Outperform (1) -
FY18 results were in line with expectations and adjusted net profit up 17.2%. Credit Suisse observes a return to growth in market share in North America is key to the outlook and the company has stuck to prior guidance for 3-5% growth in FY19.
The company has outlined a 10-year vision for the European business, expecting to grow sales to EUR1bn from EUR300m and improve margins to above 20% from 10%.
Still, Credit Suisse notes most of the growth is yet to come from the unknown fibre cement products, and management has stressed the vision is in the embryonic stage. Outperform rating maintained. Target rises to $25.00 from $24.75.
Target price is $25.00 Current Price is $22.91 Difference: $2.09
If JHX meets the Credit Suisse target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $24.79, suggesting upside of 8.2% (ex-dividends)
The company's fiscal year ends in March.
Forecast for FY19:
Credit Suisse forecasts a full year FY19 dividend of 61.15 cents and EPS of 94.08 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 100.1, implying annual growth of N/A. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 22.9. |
Forecast for FY20:
Credit Suisse forecasts a full year FY20 dividend of 69.70 cents and EPS of 107.22 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.5, implying annual growth of 14.4%. Current consensus DPS estimate is 68.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 20.0. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Deutsche Bank rates JHX as Buy (1) -
Deutsche Bank finds the Q4 performance was better-than-expected, with an equally positive outlook. A stronger US margin plus a tax benefit from restructuring are responsible for the 'beat'.
Pricing and margin outlook remain positive, in the analysts' opinion. Their target has risen to $25.35 from $24.96. Buy rating retained.
Target price is $25.35 Current Price is $22.91 Difference: $2.44
If JHX meets the Deutsche Bank target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $24.79, suggesting upside of 8.2% (ex-dividends)
Forecast for FY19:
Current consensus EPS estimate is 100.1, implying annual growth of N/A. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 22.9. |
Forecast for FY20:
Current consensus EPS estimate is 114.5, implying annual growth of 14.4%. Current consensus DPS estimate is 68.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 20.0. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates JHX as Outperform (1) -
FY18 numbers were in line with guidance and expectations. The company has highlighted ambitious growth plans for the Fermacell business, expecting EUR1bn in revenue within 10 years.
Macquarie reduces the target to $25.90 from $26.25, largely because of higher FY19 capital expenditure, asbestos liabilities and slightly softer FY19 operating outcomes in the US. Outperform maintained.
Target price is $25.90 Current Price is $22.91 Difference: $2.99
If JHX meets the Macquarie target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $24.79, suggesting upside of 8.2% (ex-dividends)
The company's fiscal year ends in March.
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 59.32 cents and EPS of 99.94 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 100.1, implying annual growth of N/A. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 22.9. |
Forecast for FY20:
Macquarie forecasts a full year FY20 dividend of 65.76 cents and EPS of 110.12 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.5, implying annual growth of 14.4%. Current consensus DPS estimate is 68.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 20.0. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates JHX as Equal-weight (3) -
Results beat Morgan Stanley's estimates at the headline while volume was a little soft in North America. Management attributed this to softer interior volumes as a result of the removal of some product.
In FY19 the company has guided for primary demand growth of 3-5% in exteriors and 1-3% in interiors. Morgan Stanley suggests the impact from recent capacity constraints appears to have been addressed. A successful roll-out in Europe will be the next potential upside catalyst.
Equal-weight rating. Target is $23.00. Cautious industry view.
Target price is $23.00 Current Price is $22.91 Difference: $0.09
If JHX meets the Morgan Stanley target it will return approximately 0% (excluding dividends, fees and charges).
Current consensus price target is $24.79, suggesting upside of 8.2% (ex-dividends)
The company's fiscal year ends in March.
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 dividend of 55.45 cents and EPS of 94.13 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 100.1, implying annual growth of N/A. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 22.9. |
Forecast for FY20:
Morgan Stanley forecasts a full year FY20 dividend of 59.32 cents and EPS of 107.03 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.5, implying annual growth of 14.4%. Current consensus DPS estimate is 68.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 20.0. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates JHX as Lighten (4) -
Net profit in FY18 was slightly ahead of Ord Minnett's estimates. The broker believes the outlook, coupled with a strong operating performance, sets the business up well for FY19.
However, with a PE multiple of 23x on forward EPS the broker believes the share price is factoring in the growth prospects. Lighten rating maintained. Target is reduced to $22.50 from $23.50.
This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.
Target price is $22.50 Current Price is $22.91 Difference: minus $0.41 (current price is over target).
If JHX meets the Ord Minnett target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $24.79, suggesting upside of 8.2% (ex-dividends)
The company's fiscal year ends in March.
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 56.74 cents and EPS of 98.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 100.1, implying annual growth of N/A. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 22.9. |
Forecast for FY20:
Ord Minnett forecasts a full year FY20 dividend of 68.34 cents and EPS of 118.63 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.5, implying annual growth of 14.4%. Current consensus DPS estimate is 68.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 20.0. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.72
Deutsche Bank rates OFX as Hold (3) -
Deutsche Bank finds management has delivered on its promise/guidance, but tough conditions are here to stay. Hold retaing retained, as well as the $1.40 price target.
The analysts suspect competition remains fierce and the company's loyal corporate customers are keeping margin trend to the downside. There seems to have been a sharp deceleration in new client acquisitions as well.
Target price is $1.40 Current Price is $1.72 Difference: minus $0.32 (current price is over target).
If OFX meets the Deutsche Bank target it will return approximately minus 19% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates OFX as Downgrade to Neutral from Outperform (3) -
FY18 net profit was in line with expectations. The company has noted a more competitive operating environment and lower levels of currency volatility.
Macquarie was disappointed with the active client growth in FY18 and believes client acquisition and overall activity levels are necessary to support an improved outlook for profitability and earnings growth.
The broker downgrades to Neutral from Outperform. Target is raised to $1.83 from $1.71.
Target price is $1.83 Current Price is $1.72 Difference: $0.11
If OFX meets the Macquarie target it will return approximately 6% (excluding dividends, fees and charges).
The company's fiscal year ends in March.
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 6.20 cents and EPS of 8.30 cents. |
Forecast for FY20:
Macquarie forecasts a full year FY20 dividend of 6.60 cents and EPS of 8.90 cents. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates STO as Downgrade to Sell from Neutral (5) -
Now that Santos has rejected Harbour Energy's higher offer, Citi analysts suggest the company narrative will shift towards growth in the coming months. They also point out, the fact that Harbour Energy said it wasn't impressed from the due diligence "complicates" things just a tad more.
As Citi has reverted back to a Sum-of-the-Parts (SoTP) methodology to value the shares, including long-term oil priced at US$55/bbl, the rating falls to Sell from Neutral. New price target is $5.30.
Target price is $5.30 Current Price is $5.86 Difference: minus $0.56 (current price is over target).
If STO meets the Citi target it will return approximately minus 10% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $5.73, suggesting downside of -2.2% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY18:
Citi forecasts a full year FY18 dividend of 4.90 cents and EPS of 26.95 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 30.4, implying annual growth of N/A. Current consensus DPS estimate is 0.8, implying a prospective dividend yield of 0.1%. Current consensus EPS estimate suggests the PER is 19.3. |
Forecast for FY19:
Citi forecasts a full year FY19 dividend of 14.06 cents and EPS of 28.11 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 31.4, implying annual growth of 3.3%. Current consensus DPS estimate is 9.3, implying a prospective dividend yield of 1.6%. Current consensus EPS estimate suggests the PER is 18.7. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates STO as Neutral (3) -
Santos has rejected Harbour Energy's final proposal of US$5.21 a share. While Harbour Energy had indicated it would increase the offer to US$5.25 if Santos was willing to extend oil price hedging arrangements it had stated that this proposal was its best and final offer.
UBS notes the share price has traded at a significant discount to the bid price in recent days, attributed to concerns that Santos would reject the bid and/or regulatory approval would not be obtained. Harbour Energy cannot return with another bid for six months. Neutral rating and $6.40 target maintained.
Target price is $6.40 Current Price is $5.86 Difference: $0.54
If STO meets the UBS target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $5.73, suggesting downside of -2.2% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY18:
UBS forecasts a full year FY18 dividend of 0.00 cents and EPS of 21.92 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 30.4, implying annual growth of N/A. Current consensus DPS estimate is 0.8, implying a prospective dividend yield of 0.1%. Current consensus EPS estimate suggests the PER is 19.3. |
Forecast for FY19:
UBS forecasts a full year FY19 dividend of 7.74 cents and EPS of 23.21 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 31.4, implying annual growth of 3.3%. Current consensus DPS estimate is 9.3, implying a prospective dividend yield of 1.6%. Current consensus EPS estimate suggests the PER is 18.7. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.63
Morgans rates TNE as Hold (3) -
Timing issues once again framed the company's first half result. Morgans notes operating revenue was up 6% and expenses also up 6%. Net profit was up 1%. Guidance for the full year is in line with expectations.
The broker rates the company as high-quality, given its defensive earnings and long-term track record. Still, Morgans is conscious that the stock is trading at elevated multiples. Hold rating maintained. Target is reduced to $4.82 from $5.10.
Target price is $4.82 Current Price is $4.63 Difference: $0.19
If TNE meets the Morgans target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $5.27, suggesting upside of 13.8% (ex-dividends)
The company's fiscal year ends in September.
Forecast for FY18:
Morgans forecasts a full year FY18 dividend of 11.00 cents and EPS of 16.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.6, implying annual growth of 17.1%. Current consensus DPS estimate is 12.5, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 27.9. |
Forecast for FY19:
Morgans forecasts a full year FY19 dividend of 12.00 cents and EPS of 18.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.4, implying annual growth of 16.9%. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 23.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates TNE as Neutral (3) -
First half results were in line although FY18 guidance is -4-9% below UBS estimates. The company expects 10-15% pre-tax profit growth in FY18. This implies 17-18% growth in the second half and a substantial turnaround in consulting is required, the broker notes.
Cloud momentum remains strong and is a key supporter of earnings in the medium term. The broker requires stabilisation across the consulting and UK businesses before taking a more positive view.
Neutral rating maintained. Target is $5.30.
Target price is $5.30 Current Price is $4.63 Difference: $0.67
If TNE meets the UBS target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $5.27, suggesting upside of 13.8% (ex-dividends)
The company's fiscal year ends in September.
Forecast for FY18:
UBS forecasts a full year FY18 dividend of 14.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.6, implying annual growth of 17.1%. Current consensus DPS estimate is 12.5, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 27.9. |
Forecast for FY19:
UBS forecasts a full year FY19 dividend of 15.00 cents and EPS of 20.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.4, implying annual growth of 16.9%. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 23.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.34
Macquarie rates WAF as Outperform (1) -
The company has completed a $35m share placement to accelerate development and exploration at Sanbrado. Primary use of the new funds will be the construction of an underground decline to access the high-grade M1S deposit.
Macquarie adjusts its base case to align with the earlier underground access as well as the overall development timeline. Outperform and 50c target maintained.
Target price is $0.50 Current Price is $0.34 Difference: $0.16
If WAF meets the Macquarie target it will return approximately 47% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY18:
Macquarie forecasts a full year FY18 dividend of 0.00 cents and EPS of minus 2.60 cents. |
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 0.00 cents and EPS of minus 1.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Summaries
BBN | BABY BUNTING | Overweight - Morgan Stanley | Overnight Price $1.48 |
CLH | COLLECTION HOUSE | Hold - Morgans | Overnight Price $1.57 |
FBU | FLETCHER BUILDING | Upgrade to Neutral from Underperform - Macquarie | Overnight Price $5.99 |
GOZ | GROWTHPOINT PROP | Initiation of coverage with Hold - Ord Minnett | Overnight Price $3.43 |
HSO | HEALTHSCOPE | Neutral - Citi | Overnight Price $2.34 |
Neutral - Credit Suisse | Overnight Price $2.34 | ||
Hold - Deutsche Bank | Overnight Price $2.34 | ||
Equal-weight - Morgan Stanley | Overnight Price $2.34 | ||
Hold - Morgans | Overnight Price $2.34 | ||
Hold - Ord Minnett | Overnight Price $2.34 | ||
JHX | JAMES HARDIE | Buy - Citi | Overnight Price $22.91 |
Outperform - Credit Suisse | Overnight Price $22.91 | ||
Buy - Deutsche Bank | Overnight Price $22.91 | ||
Outperform - Macquarie | Overnight Price $22.91 | ||
Equal-weight - Morgan Stanley | Overnight Price $22.91 | ||
Lighten - Ord Minnett | Overnight Price $22.91 | ||
OFX | OZFOREX GROUP | Hold - Deutsche Bank | Overnight Price $1.72 |
Downgrade to Neutral from Outperform - Macquarie | Overnight Price $1.72 | ||
STO | SANTOS | Downgrade to Sell from Neutral - Citi | Overnight Price $5.86 |
Neutral - UBS | Overnight Price $5.86 | ||
TNE | TECHNOLOGY ONE | Hold - Morgans | Overnight Price $4.63 |
Neutral - UBS | Overnight Price $4.63 | ||
WAF | WEST AFRICAN RESOURCES | Outperform - Macquarie | Overnight Price $0.34 |
RATING SUMMARY
Rating | No. Of Recommendations |
1. Buy | 6 |
3. Hold | 15 |
4. Reduce | 1 |
5. Sell | 1 |
Wednesday 23 May 2018
Access Broker Call Report Archives here
Disclaimer:
The content of this information does in no way reflect the opinions of
FNArena, or of its journalists. In fact we don't have any opinion about
the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe
and comment on. By doing so we believe we provide intelligent investors
with a valuable tool that helps them in making up their own minds, reading
market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not
constitute an offer to sell or a solicitation to buy any security or other
financial instrument. FNArena employs very experienced journalists who
base their work on information believed to be reliable and accurate, though
no guarantee is given that the daily report is accurate or complete. Investors
should contact their personal adviser before making any investment decision.
Latest News
1 |
ASX Winners And Losers Of Today – 08-10-246:35 PM - Daily Market Reports |
2 |
Australian Broker Call *Extra* Edition – Oct 08, 20243:50 PM - Daily Market Reports |
3 |
BHP Shares Eyeing Return To $5011:30 AM - Technicals |
4 |
Audinate’s Recurring Revenue Opportunity11:00 AM - Small Caps |
5 |
Weekly Update On LICs & LITs – 07-Oct-202410:30 AM - Weekly Reports |